Elsevier

Transplantation Proceedings

Volume 45, Issue 1, January–February 2013, Pages 330-334
Transplantation Proceedings

Liver transplantation
Complications: Thrombotic
Early Aspirin Therapy May Reduce Hepatic Artery Thrombosis in Liver Transplantation

https://doi.org/10.1016/j.transproceed.2012.05.075Get rights and content

Abstract

Background

Hepatic artery thrombosis (HAT) remains among the leading causes of early graft loss after liver transplantation. Our transplant center began using universal aspirin prophylactic therapy immediately posttransplantation in 2007. The aim of this study was to determine the safety and efficacy of early aspirin therapy on clinical outcomes.

Methods

This large-scale, cross-sectional analysis included all adult liver transplantations performed between 2000 and 2009. Pediatric and multiorgan transplants were excluded. Patients were grouped and compared based on whether they received early initiation of aspirin 325 mg PO daily posttransplantation.

Results

A total of 541 adult liver transplantations occurred during the study period; 439 had complete documentation and were analyzed. Clinical outcomes show aspirin patients had similar rates of early and late HAT, but had significantly lower early HAT, defined as HAT occurring within the first 30 days posttransplant, leading to graft loss. Other clinical outcomes were similar between groups including bleeding events and wound complications.

Conclusions

Immediate initiation of aspirin therapy after liver transplantation may reduce the rate of HAT leading to early graft loss, without increasing bleeding or other complication rates.

Section snippets

Study Design and Treatment

This cross-sectional analysis included all adult OLT performed between 2000 and 2009. Patients were grouped and compared based on whether they received early posttransplant initiation of ASA. ASA therapy began once hemostasis occurred; therapy was delayed for ≤ 96 hours in cases of severe thrombocytopenia, defined as decreased platelets in the blood, reoperation, or continued bleeding. The dosage of ASA was 325 mg PO/NG daily and was continued for 3 months. After this time period, the therapy

Methods

Primary outcomes of this study included the safety and efficacy of early ASA therapy in adult liver transplantations recipients to prevent HAT. HAT was defined radiographically, usually through ultrasonography, with confirmation either by surgical exploration or angiography. Efficacy analysis included prevalence of both early HAT, defined as occurring within the first 30 days post-OLT, and late HAT, defined as occurring after the first 30 days post-OLT, with a focus on early HAT leading to

Patients

Five hundred forty-one OLT were performed at our institution between 2000 and 2009, with 72 patients being excluded (28 pediatrics, 19 multiorgan transplants, and 25 incomplete data). This left a total of 469 cases that met inclusion criteria and had complete data; these patients were analyzed in the study: 165 patients received ASA therapy and 304 patients did not. Baseline demographics between groups were similar, with the exception of age and mean liver transplantation year (Table 1).

HAT

Table 2

Discussion

An enhanced understanding of the development of HAT and interventions to minimize this potentially devastating surgical complication has become a major focus in OLT. In this study, we show that ASA therapy is both safe and effective in reducing early HAT leading to graft loss in adult OLT recipients. The incidence of early HAT leading to graft loss in the control group was found to be significantly higher when compared with the group receiving ASA therapy. In addition, there were no increases

References (15)

There are more references available in the full text version of this article.

Cited by (0)

View full text